<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765946</url>
  </required_header>
  <id_info>
    <org_study_id>MetAge</org_study_id>
    <nct_id>NCT01765946</nct_id>
  </id_info>
  <brief_title>Metformin and Longevity Genes in Prediabetes</brief_title>
  <official_title>Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pre-diabetes, a condition characterized by hyperglycaemia, is associated with increased
      cardiovascular risk and reduced life expectancy, as compared to the general population.
      AMP-activated protein kinase (AMPK) is an enzyme that plays a key role in cellular energy
      homeostasis and metabolism, and recently it has been demonstrated that AMPK regulates aging
      pathways, as well. AMPK is susceptible to modulation through pharmacologic (e.g. metformin)
      and non-pharmacologic (e.g. physical exercise) interventions. This clinical trial aims to
      describe the effects of the AMPK pathway on longevity genes and inflammation in the setting
      of pre-diabetes in vivo and in vitro. To this end, the investigators will compare treatment
      with metformin (500 mg t.i.d) for 2 months, versus placebo in pre-diabetic subjects. The
      investigators will assess expression of longevity genes SIRT1, p66Shc, p53 and mTOR in
      peripheral blood mononuclear cells (PBMCs) ex vivo. The investigators will evaluate monocyte
      polarization by flow cytometry, according to the expression of surface antigens (CD68, CCR2,
      CD163, CD206, CX3CR1) to determine the prevalence of pro- or anti-inflammatory cells.
      Inflammatory cytokines (TNF-alpha, MCP-1, IL-1, IL-6, IL-10, CCL12) will also be determined.
      In the in vitro study the investigators will evaluate the effects of AMPK activation or
      inhibition on longevity gene and protein expression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Longevity gene expression</measure>
    <time_frame>2 month after treatment</time_frame>
    <description>Change in the expression of longevity genes Sirtuin-1, p66Shc, mTor, p53 in peripheral blood mononuclear cells (PBMC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2 months after treatment</time_frame>
    <description>A dynamic measure of insulin sensitivity (Si) from the frequently sampled OGTT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte polarization status</measure>
    <time_frame>2 months after treatment</time_frame>
    <description>Polarization of circulating monocytes in M1 (CD68+CCR2+) and M2 (CX3CR1+CD163+/CD206+)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Prediabetes</condition>
  <condition>Aging</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin tablets 500 mg tid for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tables tid for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablets 500 mg tris in die (tid)</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-diabetes, defined as IFG (fasting glucose between 100 and 125 mg/dl) or IGT (2h
             post-oral glucose load (75g) between 140 and 199 mg/dl);

          -  Age 40-75 years;

          -  Both genders.

        Exclusion Criteria:

          -  Type 1 or 2 diabetes mellitus;

          -  Pregnancy, lactation;

          -  Acute, chronic or inflammatory diseases;

          -  Neoplasms;

          -  Immunological diseases, organ transplantation, steroid therapy;

          -  Uncontrolled arterial hypertension (systolic pressure &gt; 180 mmHg or diastolic &gt; 120
             mmHg);

          -  Recent(within 3 months) surgical intervention or cardiovascular accidents;

          -  Known allergy to metformin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Avogaro, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Diabetes Outpatient Clinic</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Angelo Avogaro</investigator_full_name>
    <investigator_title>Full professor of Endocrinology and Metabolism</investigator_title>
  </responsible_party>
  <keyword>Insulin resistance</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Longevity genes</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

